September 16, 2011
Posted by Admin
ACT’s Director of Regulatory Affairs Edmund Mickunas to Present at Phacilitate Cell & Gene Therapy Forum in Singapore; Reflects Growing Interest in Company and Its Programs in East AsiaGreetings,
ACT’s Director of Regulatory Affairs, Edmund “Ed” Mickunas, will be presenting on the company’s behalf at a major industry conference, the “Phacilitate Cell & Gene Therapy Forum Asia 2011,” Sept. 19-21, in Singapore.
Ed’s presentation will focus on regulatory issues surrounding human clinical trials in the field of regenerative medicine, such as our two recently-initiated trials at UCLA’s Jules Stein Eye Institute using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) for the treatment of Stargardt’s Disease and dry age-related macular degeneration (dry AMD). Ed will also discuss ACT’s preparation for our past investigational new drug (IND) application filings for these two trials.
Asia, particularly the vast market opportunity represented by the emerging markets of East and Southeast Asia, has become a major priority for ACT as a company. We are proud of the progress made thus far in our partnership with CHA Bio & Diostech Co, Ltd. (“CHA Biotech”), a leading South Korea-based biotechnology company. We are also exploring opportunities in other major markets in the region, specifically China, and are making progress in pursuing opportunities there. You may remember that earlier this year we announced that we are to be issued a broad patent on hESC-derived RPE cells in China. We will keep you updated on other goings-on for the company in East Asia and elsewhere.
Additionally, access to my recent presentation at the Rodman & Renshaw Global Investment Conference in New York is available at this link (registration required), and access to my presentation at Terrapinn’s Stem Cells USA and Regenerative Medicine Congress in Boston is available here (PDF).
Thank you.
Gary Rabin
Chairman and CEO
Advanced Cell Technology, Inc. |
